Thursday, 15 October 2026European Markets

JINHUI SHIPP TRANS Stock Bearish Momentum With A 18% Drop At Session Start On Thursday

Loading stream...

(VIANEWS) - Shares of JINHUI SHIPP TRANS (Oslo Børs All-share Index_GI: JIN.OL) fell by a staggering 18.8% to kr7.56 at 10:40 EST on Thursday, after four consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.7% to kr1,397.96, after five sequential sessions in a row of losses. This seems, up until now, a somewhat bullish trend exchanging session today.

JINHUI SHIPP TRANS's last close was kr9.40, 49.52% under its 52-week high of kr18.62.

About JINHUI SHIPP TRANS

Jinhui Shipping and Transportation Limited, an investment holding company, engages in ship chartering and owning activities worldwide. The company provides ship management and shipping agent services. As of December 31, 2021, it owned a fleet of 24 dry bulk vessels, which include 2 Post-Panamax and 22 grab lifted Supramax. The company was founded in 1987 and is based in Hong Kong, Hong Kong. Jinhui Shipping and Transportation Limited operates as a subsidiary of Jinhui Holdings Company Limited.

Earnings Per Share

As for profitability, JINHUI SHIPP TRANS has a trailing twelve months EPS of kr-1.16.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.79%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 2%, now sitting on 171.57M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

JINHUI SHIPP TRANS's EBITDA is 1.08.

More news about JINHUI SHIPP TRANS (JIN.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com